Oxford-AstraZeneca is a Good Vaccine with really bad Communication
AstraZeneca Pharma India Ltd (AZPIL) is a listed Indian subsidiary of AstraZeneca Plc. UK. It is headquartered in Bengaluru Karnataka since 1979 and employees more than 1400 people in India. AstraZeneca India is in the business of manufacturing and marketing of Pharmaceutical products in healthcare sector. Company manufactures wide variety of products in segments like Gastrointestinal, Respiratory, Cardiovascular, Neuroscience, Cancer and infection etc. diseases. AstraZeneca replaced Merck & Co. to become manufacturer of Vaccine targeting Sars-Cov-2 produced by Oxford University’s Jenner Institute and Vaccitech in the March 2020. The Oxford-AstraZeneca Vaccine program was financed by Oxford Science Innovation, Google Ventures, Sequoia Capitals and other such sponsors. On 30th Dec 2020 the vaccine was approved first by UK for their vaccination program against Covid pandemic. Since then several countries in the world approved Oxford-AstraZeneca vaccine for their Vaccination programs against Coronavirus spread. In India it is Marketed as Covishield.
AstraZeneca India Share Price
In the March 2020 when Global Markets saw bloodbath due to panic and uncertainty about n-Coronavirus pandemic. AstraZeneca India share made it’s 52 week low of 2015.40. In those days there was no vaccine available for Coronavirus and experts said it will take at least 2 to 5 years to develop an effective vaccine for the Covid-19. Stocks like Cipla, Glenmark Pharma which were manufacturer of medicines required for treating the symptoms of Covid showed good rally. Hospital and Pathology stocks saw good buying as the number of active cases of pandemic started to increase. First Pfizer and then AstraZeneca stocks started climbing up as they declared that they will work for developing Vaccines on Covid-19. Fortunately in March 2021, world has many Vaccines against Coronavirus and they are being upgraded to fight the new variants too. In India we majority of population is taking vaccine developed by Serum Institute Pune while most effective vaccine still seems to be the one which every Politician and Rich man is taking – developed by Bharat Biotech. While in Western world AstraZeneca and Pfizer are being used by large number of countries. This helped AstraZeneca India share price too. It made 52 W high of 4970 before Controversy started pulling it down again. On 26th March 2021, share price closed at 3084. Lets discuss why AstraZeneca India Share price is falling so rapidly?
Oxford-AstraZeneca Vaccine Concerns
Oxford-AstraZeneca Covid Vaccine was welcomed positively by many Scientists and Countries. They believed in its potential to protect huge population of the world from the Coronavirus Pandemic. Everything was going well until some countries from Europe decided to suspend their Vaccine Program or completely ban this vaccine due to side effect like Blood-Clotting. Millions of people have been vaccinated so far and number of people who got any side effects like Nausea, Fever, Pain are very small. But blood-clotting was much severe side effect than these hence confidence in the Vaccine started shaking. It automatically increased their confidence in Pfizer and BioNtech vaccine. The Netherland, Denmark, Ireland, Iceland and Norway were some of the countries who first suspended use of AstraZeneca Vaccine due to blood-clot issue. In 15 cases blood clot in veins and in 22 cases blood clot formation in lungs were found in European Union and Britain said the administrators who administered the Vaccine Program. Following which the rollercoaster of AstraZeneca share price started which affected AZPIL share in India too.
To answer this questions AstraZeneca came up with press-conference and claimed that their own data showed that there is no such side-effect of their Covid-19 Vaccine and it is completely safe with 79% efficacy. Here they goofed up again as US National Institutes of Allergy and Infectious Diseases (NIAID) said that company is lying and current data shows that efficacy is between 69-74%. It also criticized AstraZeneca for providing outdated information. Many experts see it as a desperation of AstraZeneca to stay in competition with Pfizer by showing higher efficacy.